Lv11
34 积分 2025-04-02 加入
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
1小时前
已完结
When a pancreatic pseudocyst is not a pseudocyst: diagnostic pitfalls and complications
1个月前
已完结
Rectal lesion with a submucosal tumour-like appearance in a middle-aged woman
1个月前
已完结
Liver disease: screening for the elusive adversary
4个月前
已完结
Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study
4个月前
已关闭
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration
4个月前
已完结
Immunotherapy of Hepatocellular Carcinoma
5个月前
已完结
Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)
5个月前
已完结
P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073
5个月前
已完结
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
5个月前
已完结
皖公网安备34019202002308
